Tenecteplase use in patients with acute ischaemic stroke

Affiliations

¹ Department of Clinical Neurosciences, and Department of Radiology, Cumming School of Medicine and Department of Community Health Sciences, University of Calgary, Calgary, AB T2N2T9, Canada; Hotchkiss Brain Institute, Calgary, AB, Canada. Electronic address: bkmmenon@ucalgary.ca.
² Department of Neurology, University of Manitoba, Winnipeg, MB, Canada.
³ Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.

Comment

Bijoy K Menon et al. Lancet. 2023.

. 2023 Feb 25;401(10377):618-619.

doi: 10.1016/S0140-6736(22)02633-2. Epub 2023 Feb 9.

¹ Department of Clinical Neurosciences, and Department of Radiology, Cumming School of Medicine and Department of Community Health Sciences, University of Calgary, Calgary, AB T2N2T9, Canada; Hotchkiss Brain Institute, Calgary, AB, Canada. Electronic address: bkmmenon@ucalgary.ca.
² Department of Neurology, University of Manitoba, Winnipeg, MB, Canada.
³ Comprehensive Stroke Care Program, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.

No abstract available

Comment on

Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, Schwamm LH, Fisher M, Che F, Dai H, Li D, Li R, Wang J, Wang Y, Zhao X, Li Z, Zheng H, Xiong Y, Meng X; TRACE-2 Investigators. Wang Y, et al. Lancet. 2023 Feb 25;401(10377):645-654. doi: 10.1016/S0140-6736(22)02600-9. Epub 2023 Feb 9. Lancet. 2023. PMID: 36774935 Clinical Trial.